Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Anti-metastatic treatment in colorectal cancer: targeting signaling pathways

Item Type:Article
Title:Anti-metastatic treatment in colorectal cancer: targeting signaling pathways
Creators Name:Lemos, C. and Sack, U. and Schmid, F. and Juneja, M. and Stein, U.
Abstract:Colorectal cancer is one of the most common cancers worldwide and one of the leading causes of cancer-related death in the Western world. Tumor progression towards metastasis affects a large number of patients with colorectal cancer and seriously affects their clinical outcome. Therefore, considerable effort has been made towards the development of therapeutic strategies that can decrease or prevent colorectal cancer metastasis. Standard treatment of metastatic colorectal cancer with chemotherapy has been improved in the last 10 years by the addition of new targeted agents. The currently used antibodies bevacizumab, cetuximab and panitumumab target the VEGF and EGFR signaling pathways, which are crucial for tumor progression and metastasis. These antibodies have shown relevant efficacy in both first- and second-line treatment of metastatic colorectal cancer. Additionally, other signaling pathways, including the Wnt and HGF/Met pathways, have a well-established role in colorectal cancer progression and metastasis and constitute, therefore, promising targets for new therapeutic approaches. Several new drugs targeting these pathways, including different antibodies and small-molecule tyrosine kinase inhibitors, are currently being developed and tested in clinical trials. In this review, we summarize the new developments in this field, focusing on the inhibitors that show more promising results for use in colorectal cancer patients.
Keywords:Colorectal Cancer, HGF/Met Pathway, Metastasis, Molecular Therapeutics, Wnt/beta-Catenin Pathway, Tumor, Chemotherapy, Bevacizumab, Cetuximab, Panitumumab, Animals
Source:Current Pharmaceutical Design
ISSN:1381-6128
Publisher:Bentham Science Publishers (The Netherlands)
Volume:19
Number:5
Page Range:841-863
Date:February 2013
Official Publication:https://doi.org/10.2174/1381612811306050841
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library